Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/09/2018|
|Rapid review completed||11/10/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.|